STOCK TITAN

GRI Bio (GRI) SEC Filings, Jun-Aug 2025

GRI NASDAQ

GRI Bio filings document a clinical-stage biotechnology issuer developing Natural Killer T cell modulators and the public-company events tied to that business. The filings include 8-K disclosures covering GRI-0621 clinical trial updates in idiopathic pulmonary fibrosis, financial-result releases and press-release exhibits furnished under results of operations and other-events items.

The filing record also details capital structure and governance matters, including at-the-market common stock offering agreements and prospectus supplements, legal opinions for share issuance, certificate amendments for a reverse stock split, Nasdaq Capital Market compliance notices, special meeting voting results and adjustments affecting common stock, warrants, convertible securities and equity incentive plans.

Rhea-AI Summary

GRI Bio, Inc. reported results from its August 13, 2025 virtual Annual Meeting. Stockholders approved an amendment to the Amended and Restated 2018 Equity Incentive Plan, increasing the number of shares reserved for issuance by 400,000 shares. The company noted 2,496,800 shares issued and outstanding as of the July 8, 2025 record date and a quorum of 1,090,373 shares (approximately 43.67%) was present or represented.

At the meeting the board nominees Roelof Rongen and Camilla V. Simpson were elected with 63,031 and 63,581 votes for, respectively, and the appointment of WithumSmith+Brown, PC as independent registered public accounting firm for fiscal 2025 was ratified with 1,072,167 votes for. Exhibit 10.1 contains the amended equity incentive plan text.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.77%
Tags
current report
-
Form 8-K
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-37.56%
Tags
current report
-
ARS
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.45%
Tags
annual report
DEF 14A
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.45%
Tags
proxy
-
Form 8-K
Rhea-AI Summary

GRI Bio (Nasdaq: GRI) furnished an 8-K under Item 7.01 disclosing a press release that reports interim safety results from its Phase 2a study of GRI-0621 for idiopathic pulmonary fibrosis. The disclosure is provided solely for Regulation FD purposes and is expressly not deemed “filed” under the Exchange Act. No efficacy data, financial metrics, or guidance updates were included. Exhibit 99.1 contains the full press release; no other material items were reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.19%
Tags
current report

FAQ

How many GRI Bio (GRI) SEC filings are available on StockTitan?

StockTitan tracks 65 SEC filings for GRI Bio (GRI), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for GRI Bio (GRI)?

The most recent SEC filing for GRI Bio (GRI) was filed on November 13, 2026.